Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• MYC 0
• ERK 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

24 of 61+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Artificial Intelligence Enhanced Detection and Monitoring of Bladder Cancer

  Vesica Corporation· San Marcos, United States· US$1,200,764 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort

  Veterans Education/Res/Assn/North/Ne· White River Junction, United States· US$594,869 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Population modeling for bladder cancer prevention and control

  Brown University· Providence, United States· US$1,231,387 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · P50

  SPORE in Bladder Cancer

  Sloan-Kettering Inst Can Research· New York, United States· US$2,491,899 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the effect of high methionine availability on cancer progression

  University of Southern California· Los Angeles, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

10 of 192 running projects, newest first. Listed amounts together: US$123.2m + €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Kinnate Biopharma· Updated 7 May 2025

  “Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor prior to enrollment into the dose expansion part of the study (Part B).”Registry text, quoted unchanged. Source

• Terminated

  Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

  NCT04228042· M.D. Anderson Cancer Center· Updated 1 Jan 2025

  “Drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

  NCT04963153· National Cancer Institute (NCI)· Source

• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Janssen Research & Development, LLC· Source

• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

  NCT05567185· Janssen Pharmaceutical K.K.· Source

• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Janssen Research & Development, LLC· Source

• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.

  2023-507684-19-00· Janssen Cilag International· Source

• A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

  NCT07827612· Eli Lilly and Company· Source

• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Eli Lilly and Company· Source

• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

  NCT04917809· Memorial Sloan Kettering Cancer Center· Source

• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Janssen Research & Development, LLC· Source

• A Phase 2 Clinical Study of ABSK061 and ABSK043

  NCT06632262· Abbisko Therapeutics Co, Ltd· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 79
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 78
• Genome-Wide Association Study 18

• Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort.

  JCO Precis Oncol, Nov 2026

• Elevated Risk of Bladder Cancer Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease in Elderly Korean Men: A Nationwide Cohort Study.

  J Korean Med Sci, Nov 2026

• Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer.

  JCO Precis Oncol, Nov 2026

• Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study.

  Anticancer Res, Nov 2026

• Clinical response outweighs baseline nodal stage in treatment selection and survival of clinically node-positive bladder cancer.

  World J Urol, Oct 2026

• FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.

  Medicina (Kaunas), Oct 2026

• Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.

  ESMO Open, Sept 2026

• Oncological and perioperative outcomes of robot-assisted radical cystectomy: a real-world cohort study emulating a target trial.

  J Robot Surg, Sept 2026

• Soy Consumption and the Risk of Developing Bladder Cancer: A Pooled Analysis of Cohort Studies from the International Pooled Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study.

  Nutrients, Sept 2026

• Association between cervical human papillomavirus infection and bladder cancer risk: A community-based cohort study.

  J Infect Public Health, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.